Among patients previously treated with 1 TNF inhibitor , sustained ustekinumab efficacy was also observed ( week 24 combined vs placebo : ACR20 35.6 % vs 14.5 % , PASI75 47.1 % vs 2.0 % , median HAQ-DI change -0.13 vs 0.0 ; week 52 ustekinumab-treated : ACR20 38.9 % , PASI75 43.4 % , median HAQ-DI change -0.13 ) .